Trials / Terminated
TerminatedNCT07039929
Study to Assess the Safety, Tolerability, and Pharmacokinetics of INCB000631 When Administered Orally to Healthy Adult Participants
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of INCB000631 When Administered Orally to Healthy Adult Participants
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Incyte Corporation · Industry
- Sex
- All
- Age
- 19 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This study will be conducted to assess the safety, tolerability, and pharmacokinetics of INCB000631 when administered orally to healthy adult participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | INCB000631 | Oral; Tablet |
| DRUG | Placebo | Oral; Tablet |
Timeline
- Start date
- 2025-07-28
- Primary completion
- 2025-10-11
- Completion
- 2025-10-11
- First posted
- 2025-06-26
- Last updated
- 2025-10-29
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07039929. Inclusion in this directory is not an endorsement.